Clinical Trials Directory

Trials / Completed

CompletedNCT00014742

Phase III Randomized Study of Collagenase in Patients With Residual Stage Dupuytren's Disease

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
72 (estimated)
Sponsor
State University of New York · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

OBJECTIVES: I. Compare the safety and efficacy of clostridial collagenase vs placebo in terms of improving the degree of flexion deformity, range of finger motion, and grip strength in patients with residual stage Dupuytren's disease. II. Compare the overall clinical success rate, time to return to normal finger contracture to within 0-5 degrees of normal (zero degrees), and frequency of cord rupture in the joint of patients treated with these regimens. III. Compare the baseline change in degree of finger flexion deformity, range of motion of the treated finger, and strength of hand grip (in pounds) in patients treated with these regimens. IV. Compare the frequency distribution of the number of patients with reduction in finger contracture to within 0-5 degrees of normal (zero degrees) and the number who require re-treatment with open-label collagenase after treatment with these regimens.

Detailed description

PROTOCOL OUTLINE: This is a randomized, investigator-blinded, placebo-controlled, multicenter study. Patients are randomized to one of two treatment arms. Arm I: Patients receive a single collagenase injection into the target finger cord on day 0. Arm II: Patients receive a single placebo injection as in arm I. Both arms: After the 1 month evaluation, patients who are unresponsive to treatment may receive monthly injections of collagenase for a maximum of 5 injections. Beginning at 1 day after completion of treatment, patients use a joint nighttime extension splint for 4 months and perform finger flexion/extension exercises. Patients are followed at 1, 7, and 14 days, monthly for 3 months, every 3 months for 9 months, and then annually for 4 years. Completion date provided represents the completion date of the grant per OOPD records

Conditions

Interventions

TypeNameDescription
DRUGcollagenase

Timeline

Completion
2004-04-01
First posted
2001-04-11
Last updated
2015-03-25

Source: ClinicalTrials.gov record NCT00014742. Inclusion in this directory is not an endorsement.